211 related articles for article (PubMed ID: 25344581)
1. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression.
Kim JM; Jeung HC; Rha SY; Yu EJ; Kim TS; Shin YK; Zhang X; Park KH; Park SW; Chung HC; Powis G
Mol Cancer Ther; 2014 Dec; 13(12):3074-85. PubMed ID: 25344581
[TBL] [Abstract][Full Text] [Related]
2. RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo.
Chang L; Gong F; Cui Y
Mol Med Rep; 2015 Jul; 12(1):1197-204. PubMed ID: 25778452
[TBL] [Abstract][Full Text] [Related]
3. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer.
Carl-McGrath S; Lendeckel U; Ebert M; Roessner A; Röcken C
Int J Oncol; 2005 Jan; 26(1):17-24. PubMed ID: 15586220
[TBL] [Abstract][Full Text] [Related]
4. ADAM9 silencing inhibits breast tumor cell invasion in vitro.
Micocci KC; Martin AC; Montenegro Cde F; Durante AC; Pouliot N; Cominetti MR; Selistre-de-Araujo HS
Biochimie; 2013 Jul; 95(7):1371-8. PubMed ID: 23499592
[TBL] [Abstract][Full Text] [Related]
5. MiR-126 regulated breast cancer cell invasion by targeting ADAM9.
Wang CZ; Yuan P; Li Y
Int J Clin Exp Pathol; 2015; 8(6):6547-53. PubMed ID: 26261534
[TBL] [Abstract][Full Text] [Related]
6. RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells.
Xu Q; Liu X; Cai Y; Yu Y; Chen W
Tumour Biol; 2010 Jun; 31(3):217-24. PubMed ID: 20422344
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA‑302a suppresses cell proliferation, migration and invasion in osteosarcoma by targeting ADAM9.
Yang X; Cui Y; Yang F; Sun C; Gao X
Mol Med Rep; 2017 Sep; 16(3):3565-3572. PubMed ID: 28713950
[TBL] [Abstract][Full Text] [Related]
8. ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126.
Wang J; Zhou Y; Fei X; Chen X; Yan J; Liu B; Zhu Z
Oncol Rep; 2017 Apr; 37(4):2033-2040. PubMed ID: 28260063
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the A disintegrin and metalloproteinase 9 in oral cancer cell invasion.
Buranaphatthana W; Wu S; Makeudom A; Sastraruji T; Supanchart C; Krisanaprakornkit S
Eur J Oral Sci; 2021 Jun; 129(3):e12775. PubMed ID: 33786875
[TBL] [Abstract][Full Text] [Related]
10. MiR-129-5p functions as a tumor suppressor in gastric cancer progression through targeting ADAM9.
Liu Q; Jiang J; Fu Y; Liu T; Yu Y; Zhang X
Biomed Pharmacother; 2018 Sep; 105():420-427. PubMed ID: 29879625
[TBL] [Abstract][Full Text] [Related]
11. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form.
Mongaret C; Alexandre J; Thomas-Schoemann A; Bermudez E; Chéreau C; Nicco C; Goldwasser F; Weill B; Batteux F; Lemare F
Int J Cancer; 2011 Aug; 129(4):791-8. PubMed ID: 21064090
[TBL] [Abstract][Full Text] [Related]
12. microRNA-1298 inhibits the malignant behaviors of breast cancer cells via targeting ADAM9.
Chen W; Lu Q; Li S; Zhang X; Xue X
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33146718
[TBL] [Abstract][Full Text] [Related]
13. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
Hamada S; Satoh K; Fujibuchi W; Hirota M; Kanno A; Unno J; Masamune A; Kikuta K; Kume K; Shimosegawa T
Mol Cancer Res; 2012 Jan; 10(1):3-10. PubMed ID: 22064652
[TBL] [Abstract][Full Text] [Related]
14. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.
Kossmann CM; Annereau M; Thomas-Schoemann A; Nicco-Overney C; Chéreau C; Batteux F; Alexandre J; Lemare F
Tumour Biol; 2017 Jul; 39(7):1010428317716077. PubMed ID: 28675123
[TBL] [Abstract][Full Text] [Related]
15. Recombinant disintegrin domain of human ADAM9 inhibits migration and invasion of DU145 prostate tumor cells.
Martin AC; Cardoso AC; Selistre-de-Araujo HS; Cominetti MR
Cell Adh Migr; 2015; 9(4):293-9. PubMed ID: 26211476
[TBL] [Abstract][Full Text] [Related]
16. Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.
Moriwaki M; Le TT; Sung SY; Jotatsu Y; Yang Y; Hirata Y; Ishii A; Chiang YT; Chen KC; Shigemura K; Fujisawa M
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740916
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA‑543 inhibits proliferation, invasion and induces apoptosis of glioblastoma cells by directly targeting ADAM9.
Ji T; Zhang X; Li W
Mol Med Rep; 2017 Nov; 16(5):6419-6427. PubMed ID: 28849046
[TBL] [Abstract][Full Text] [Related]
18. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.
Chiu KL; Lin YS; Kuo TT; Lo CC; Huang YK; Chang HF; Chuang EY; Lin CC; Cheng WC; Liu YN; Lai LC; Sher YP
Oncotarget; 2017 Jul; 8(29):47365-47378. PubMed ID: 28537886
[TBL] [Abstract][Full Text] [Related]
19. Stabilization of ADAM9 by N-α-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer.
Lin YW; Wen YC; Chu CY; Tung MC; Yang YC; Hua KT; Pan KF; Hsiao M; Lee WJ; Chien MH
Cell Death Dis; 2020 Jul; 11(7):591. PubMed ID: 32719332
[TBL] [Abstract][Full Text] [Related]
20. Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways.
Huang CF; Yang SF; Chiou HL; Hsu WH; Hsu JC; Liu CJ; Hsieh YH
Food Funct; 2018 Dec; 9(12):6196-6204. PubMed ID: 30465574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
